Charles River Laboratories International (CRL) DCF: History & Chart

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$280.76+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

Charles River Laboratories International, Inc. (CRL) DCF Valuation

Why we don't show a single “fair value” for CRL

Even the optimistic scenario of a conservative trailing-FCF model ($108.03) sits far below today's price — the market is paying for growth and durability beyond what this model structure captures. The honest lens is the question below: what growth does today's price actually require? The model scenarios are listed further down for reference.

What would today's price require?

Growth the price assumes+31.3%/yr

Actual FCF growth, last 5 years+6.4%/yr

$280.76 is justified only if free cash flow grows about +31.3% a year (fading to 2.5% long-run) at a 10.9% required return — faster than the company has actually grown.

Scenario	FCF growth (fading to 2.5%)	Discount	Value / share
Conservative	2.3%/yr	11.9%	$47.68
Base case	5.3%/yr	10.9%	$73.13
Optimistic	8.3%/yr	9.9%	$108.03
Third-party model estimate (FMP)	independent reference · retrieved Sep 8, 2026 · assumptions not provided		$87.99

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Price|PE Ratio|FCF Yield|All Metrics

Current Price

$280.76

Market-Implied Growth

+31.3%/yr

vs +6.4% 5Y actual

Base-Case Model Value

$73.13

model output — not a price target

CRL DCF Fair Value Calculator

Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for CRL (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.

FCF Growth Rate5.3%/yr

Historical FCF CAGR: 3Y 9.6% · 5Y 6.4% · 10Y 4.2%

Discount Rate (WACC)10.9%

Terminal Growth2.5%

Projection Years10yr

Base inputs: FCF $433.5M · 0.05B shares · net debt $2.4B

Estimated Fair Value

$73.13

-74.0% vs $280.76

Current price$280.76

Third-party model estimate (FMP)$87.99

Sensitivity — fair value by discount rate × terminal growth

How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 5.3%/yr FCF growth and 10-year horizon fixed. Green = above today's $280.76; red = below. Your current case is outlined.

WACC ↓ / Terminal →	1.50%	2.00%	2.50%	3.00%	3.50%
8.9%	$94.59	$103	$112	$123	$136
9.9%	$77.01	$83.12	$90.05	$97.97	$107
10.9%	$63.19	$67.88	$73.13	$79.03	$85.71
11.9%	$52.04	$55.74	$59.82	$64.35	$69.42
12.9%	$42.86	$45.83	$49.08	$52.65	$56.60